Medtronic’s Companion Medical Acquisition: Exploring the Impetus with MDT's Mike Hill

article image

Medtronic’s latest tuck-in acquisition in the diabetes space, smart insulin pen company Companion Medical, gets Medtronic in on the “ground floor” of a huge and largely untapped growth opportunity, according to Mike Hill, VP of Marketing Analytics and Operations for Medtronic diabetes. What’s more, it could help the company inch toward a more collaborative diabetes business model.

In mid-August, Medtronic plc announced that it had reached a deal to acquire privately held smart insulin pen company Companion Medical for an undisclosed amount, taking Medtronic’s diabetes business in a new direction. Companion’s InPen system—the first smart insulin pen to receive FDA clearance (in 2016)—combines a Bluetooth-enabled insulin pen that automatically tracks insulin doses with a mobile app that monitors trends, keeps track of missed doses, sends dosing reminders, and calculates appropriate doses based on meal estimations.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: